Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.24B | 4.40B | 7.63B | 8.44B | 6.82B | 5.44B |
Gross Profit | 2.31B | 2.47B | 5.00B | 5.70B | 4.45B | 3.38B |
EBITDA | 841.40M | 1.04B | 3.44B | 4.10B | 2.87B | 1.83B |
Net Income | -148.40M | -500.00K | 1.91B | 2.24B | 1.29B | 349.40M |
Balance Sheet | ||||||
Total Assets | 14.98B | 15.37B | 15.87B | 16.37B | 16.20B | 16.48B |
Cash, Cash Equivalents and Short-Term Investments | 566.50M | 771.70M | 319.70M | 234.00M | 319.40M | 282.00M |
Total Debt | 5.49B | 5.67B | 6.03B | 6.60B | 7.85B | 9.07B |
Total Liabilities | 8.12B | 8.30B | 9.22B | 9.86B | 10.30B | 11.14B |
Stockholders Equity | 6.86B | 7.08B | 6.66B | 6.51B | 5.89B | 5.34B |
Cash Flow | ||||||
Free Cash Flow | 725.60M | 772.10M | 2.61B | 3.13B | 2.47B | 1.82B |
Operating Cash Flow | 796.60M | 898.10M | 2.89B | 3.62B | 2.84B | 1.92B |
Investing Cash Flow | -199.20M | -287.80M | -392.10M | -599.50M | -477.70M | -173.30M |
Financing Cash Flow | -346.00M | -158.30M | -2.41B | -3.10B | -2.33B | -1.86B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $40.03B | 21.76 | 66.50% | 0.68% | 34.30% | 352.35% | |
76 Outperform | $59.21B | 27.75 | 23.11% | 1.74% | -7.53% | -21.88% | |
74 Outperform | $11.12B | 29.86 | 6.61% | 3.85% | -8.24% | -48.31% | |
69 Neutral | $20.28B | 46.27 | 5.72% | ― | -17.93% | -75.83% | |
66 Neutral | $24.06B | 38.30 | 3.72% | 1.16% | -22.97% | -78.58% | |
61 Neutral | $35.45B | 8.20 | -10.60% | 1.91% | 8.56% | -9.51% | |
53 Neutral | $35.08B | 84.25 | -2.24% | 2.86% | -35.70% | -113.08% |
At the annual meeting of stockholders held on August 19, 2025, Microchip‘s stockholders elected several individuals to the Board of Directors, including Ellen L. Barker, Rick Cassidy, Matthew W. Chapman, Victor Peng, Karen M. Rapp, and Steve Sanghi. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026, was ratified. However, the proposal to approve the compensation of named executives on an advisory basis was not approved.